News & Updates

Resistance exercise training counters the negative effects of androgen deprivation therapy (ADT) and improves muscle fibre size, as well as capillarization, in patients with prostate cancer, reports a study.

Immune-related adverse events (irAEs) are more likely to develop in metastatic nonsmall cell lung cancer (NSCLC) patients with certain prognostic characteristics, suggests a study. Interestingly, those who develop irAEs benefit from a much longer overall survival (OS) and time to next treatment when mitigating immortal time bias.

Treatment with canakinumab appears beneficial to patients with advanced nonsmall cell lung cancer (NSCLC) with low T-cell infiltration (ie, low total count or immune desert phenotype), results of predefined exploratory biomarker analyses from the CANOPY-1 have shown.

For patients with HER2-positive early breast cancer (BC), 1 year of adjuvant trastuzumab remains standard of care (SoC) as noninferiority is not demonstrated for a shortened 9-week course of treatment in the final analysis of the phase III ShortHER trial. However, long-term data from the trial provide reassurance in case early discontinuation is needed in low-risk patients.

Patients with previously untreated, locally advanced, or metastatic squamous non-small-cell lung cancer (NSCLC) may derive benefit from the addition of the novel anti-PD-1 monoclonal antibody serplulimab to chemotherapy, according to the final analysis of the phase III ASTRUM-004 study.

Trastuzumab deruxtecan (T-DXd) at both 5.4 mg/kg and 6.4 mg/kg doses provides clinically meaningful and durable responses in patients with previously treated HER2-mutant (HER2m) metastatic non-small-cell lung cancer (mNSCLC), with the 5.4 mg/kg dose showing a more favourable benefit/risk profile, according to primary results of the phase II DESTINY-Lung02 trial.

Visceral fat area (VFA) is a reliable prognostic indicator of muscle mass and is associated with nutritional, immune, and inflammatory status in patients with diverse types of cancer, such as gastric, colorectal, and nonsmall-cell lung cancers (NSCLC), claims a recent study.

In the phase III INSPIRE study, the novel, potent ALK tyrosine kinase inhibitor (TKI) iruplinalkib conferred a progression-free survival (PFS) benefit in patients with TKI-naïve, locally advanced, or metastatic ALK+ non-small-cell lung cancer (NSCLC).